We can’t show the full text here under this license. Use the link below to read it at the source.
Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective
Current Use of Glucagon-like Peptide-1 Receptor Agonists in Fatty Liver Disease Linked to Metabolic Problems
AI simplified
Page updated
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may offer significant benefits in managing metabolic dysfunction-associated steatotic liver disease ().
- MASLD is linked to severe health issues, including cirrhosis and mortality.
- Lifestyle changes are critical for managing MASLD but are often difficult to maintain long-term.
- GLP-1RAs have shown promising effects in both preclinical and clinical studies for MASLD treatment.
- The article reviews the therapeutic advantages of GLP-1RAs for liver health.
- Key discussions include optimal trial endpoints and management of related health conditions.
AI simplified
Key numbers
46.1 to 46.9 new cases per 1,000 person-years
Incidence of
Reflects the overall incidence of in the population.
30.05% to 32.4%
Prevalence of
Estimates the prevalence of in the general population.
21% and 63% for and MASH, respectively
Projected increase in cases
Anticipated rise in cases of and metabolic dysfunction-associated steatohepatitis (MASH).